Posted by desolationrower on September 20, 2009, at 4:10:45
Maybe someones still having akathisia. i remember people with it before, maybe someone will remember/find this thread next time someone comes around asking about it, which probably won't be too long if abilify keeps getting rxed.
N-Acetyl Cysteine as a Glutathione Precursor for SchizophreniaA Double-Blind, Randomized, Placebo-Controlled Trial
Michael Berkabc, David Copolovad, Olivia Deanae, Kristy Lub, Sue Jeavonsfg, Ian Schapkaitzb, Murray Anderson-Huntb, Fiona Juddf, Fiona Katzg, Paul Katzg, Sean Ording-Jesperseng, John Littleh, Philippe Conusj, Michel Cuenodj, Kim Q. Doj, Ashley I. BushaikCorresponding Author Informationemail address
Received 16 November 2007; received in revised form 29 February 2008; accepted 3 March 2008. published online 24 April 2008.
BackgroundBrain glutathione levels are decreased in schizophrenia, a disorder that often is chronic and refractory to treatment. N-acetyl cysteine (NAC) increases brain glutathione in rodents. This study was conducted to evaluate the safety and effectiveness of oral NAC (1 g orally twice daily [b.i.d.]) as an add-on to maintenance medication for the treatment of chronic schizophrenia over a 24-week period.
MethodsA randomized, multicenter, double-blind, placebo-controlled study. The primary readout was change from baseline on the Positive and Negative Symptoms Scale (PANSS) and its components. Secondary readouts included the Clinical Global Impression (CGI) Severity and Improvement scales, as well as general functioning and extrapyramidal rating scales. Changes following a 4-week treatment discontinuation were evaluated. One hundred forty people with chronic schizophrenia on maintenance antipsychotic medication were randomized; 84 completed treatment.
ResultsIntent-to-treat analysis revealed that subjects treated with NAC improved more than placebo-treated subjects over the study period in PANSS total [−5.97 (−10.44, −1.51), p = .009], PANSS negative [mean difference −1.83 (95% confidence interval: −3.33, −.32), p = .018], and PANSS general [−2.79 (−5.38, −.20), p = .035], CGI-Severity (CGI-S) [−.26 (−.44, −.08), p = .004], and CGI-Improvement (CGI-I) [−.22 (−.41, −.03), p = .025] scores. No significant change on the PANSS positive subscale was seen. N-acetyl cysteine treatment also was associated with an improvement in akathisia (p = .022). Effect sizes at end point were consistent with moderate benefits.
ConclusionsThese data suggest that adjunctive NAC has potential as a safe and moderately effective augmentation strategy for chronic schizophrenia.
-d/r
poster:desolationrower
thread:917764
URL: http://www.dr-bob.org/babble/20090912/msgs/917764.html